Please note that this website is not an official website of Atrium Wake Forest Baptist Health or Wake Forest University School of Medicine. This site was created to inform others about the research activities and work conducted in the Section on Infectious Diseases as part of our wider social media presence.
Dr. Williamson has 25 years of experience conducting outcomes research and clinical trials, with a focus on antimicrobials and vaccines. Much of his research efforts have been devoted to ensuring the safe and effective use of medications. Prior works of his have involved efficacy evaluations of antimicrobials, characterization of antibiotic resistance, optimizing medication dosing, utilizing rapid diagnostic tests, and evaluations of antiretroviral safety. Most recently, Dr. Williamson is working to develop novel therapeutics for trichomonas and prophylactic agents to prevent norovirus gastroenteritis and combat wound infections.
Recent publications
Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial.
Jo J, Carlson TJ, Hu C, Williamson JC, Belin YT, Horvath TD, Haidacher SJ, Bassères E, Begum K, Alam MJ, Garey KW
Journal: The Journal of antimicrobial chemotherapy · Publish Date: 2025 Oct 3 · DOI: 10.1093/jac/dkaf278 · PMID: 40796204
Nitazoxanide and tizoxanide demonstrate high levels of in vitro activity against metronidazole-susceptible and metronidazole-resistant Trichomonas vaginalis clinical isolates.
In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates.
Analysis of infections among patients with historical culture positive for extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae: Is ESBL-targeted therapy always needed?
Stone TJ, DeWitt M, Johnson JW, Beardsley JR, Munawar I, Palavecino E, Luther VP, Ohl CA, Williamson JC
Analysis of accumulated SARS-CoV-2 seroconversion in North Carolina: The COVID-19 Community Research Partnership.
Williamson JC, Wierzba TF, Santacatterina M, Munawar I, Seals AL, Pittman Ballard CA, Alexander-Miller M, Runyon MS, McCurdy LH, Gibbs MA, Ahmed A, Lagarde WH, Maguire PD, King-Thiele R, Hamrick T, Ihmeidan A, Henderson S, Gallaher TR, Uschner D, Edelstein SL, Herrington DM, Sanders JW, North Carolina sites of the COVID-19 Community Research Partnership
